10-K: Zymeworks Shifts to Royalty Focus, Reports $81.1M Loss

Zymeworks Inc. reports a net loss of $81.1 million for 2025, alongside significant regulatory approvals for zanidatamab and a new $250 million royalty financing deal.

Summary

• Zymeworks reported a net loss of $81.1 million for the year ended December 31, 2025, with an accumulated deficit of $953.2 million.
• Revenue from research and development collaborations increased by $29.7 million to $106.0 million in 2025, driven by milestone payments from partners.
• Research and development expenses increased slightly by $2.4 million to $137.0 million in 2025, reflecting a shift in program mix and increased investment in early-stage programs.
• General and administrative expenses remained consistent at $61.5 million in 2025.
• The company secured a $250.0 million non-recourse, secured term loan from Royalty Pharma on March 2, 2026, by selling 30% of future Ziihera royalties.
• Ziihera (zanidatamab-hrii) received accelerated FDA approval in November 2024 for HER2+ biliary tract cancer (BTC), conditional marketing authorization from the European Commission in July 2025, and NDS approval from Health Canada in January 2026.
• Positive topline results from the Phase 3 HERIZON-GEA-01 trial for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma (GEA) were announced in November 2025, showing prolonged progression-free survival and overall survival benefits.
• Jazz Pharmaceuticals expects to complete the sBLA submission for zanidatamab in 1L HER2+ GEA in Q1 2026, with a potential commercial launch in H2 2026.
• Pasritamig (JNJ-78278343), a bispecific T cell engager, entered multiple Phase 3 clinical trials in September 2025 for castration-resistant prostate cancer.
• The ZW171 clinical development program was discontinued in September 2025, and development of ZW220 was paused to accelerate ZW251.
• The company is advancing wholly-owned ADC candidates ZW191 (Phase 1, targeting FR-expressing tumors) and ZW251 (Phase 1, targeting GPC3-expressing HCC), and MSAT candidates ZW209 (TriTCE, targeting DLL3) and ZW1528 (IL-4R x IL-33 bispecific for AIID), with IND/regulatory filings expected in 2026.
• A new $125.0 million share repurchase program was authorized in November 2025, with approximately $62.5 million utilized by February 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, driven by significant regulatory approvals and positive clinical data for key partnered assets, which validate its technology and royalty aggregation strategy. However, continued net losses and the need for ongoing external funding temper the overall sentiment.

Positives

• Ziihera (zanidatamab-hrii) received accelerated approval from the FDA in November 2024 for HER2+ biliary tract cancer (BTC).
• The European Commission granted conditional marketing authorization for Ziihera in HER2+ BTC in July 2025.
• Health Canada approved the New Drug Submission for Ziihera in HER2+ BTC in January 2026.
• The UK's MHRA approved zanidatamab for BTC in February 2026.
• Positive topline results from the Phase 3 HERIZON-GEA-01 trial for zanidatamab in first-line HER2+ GEA demonstrated clinically meaningful and statistically significant prolongation of progression-free survival (PFS) with approximately 35% reduction in disease progression or death versus trastuzumab and chemotherapy.
• Ziihera plus tislelizumab and chemotherapy showed a statistically significant and clinically meaningful overall survival (OS) benefit with a median OS of 26.4 months in HER2+ GEA.
• Pasritamig (JNJ-78278343) initiated multiple Phase 3 clinical trials in September 2025 for castration-resistant prostate cancer, triggering a $25.0 million milestone payment from J&J.
• Received $69.9 million in milestone payments, an option exercise fee, and a research period extension fee from collaboration partners in 2025.
• The Royalty Pharma loan arrangement provided $250.0 million in non-dilutive funding on March 2, 2026.
• The company's proprietary Azymetric technology was validated by the FDA approval of zanidatamab in 2024.
• ZW191 achieved a highest non-severely toxic dose (HNSTD) of 60 mg/kg in non-human primates, suggesting potential for efficacious doses in Phase 1 trials.
• ZW251 achieved an HNSTD of 100 mg/kg in non-human primates, suggesting potential for high doses in humans.
• The company's cash, cash equivalents, and marketable securities of $270.6 million as of December 31, 2025, are anticipated to fund operating and capital expenditures for at least the next twelve months.

Negatives

• Reported a net loss of $81.1 million for the year ended December 31, 2025.
• Accumulated deficit reached $953.2 million as of December 31, 2025.
• Cash used in operating activities was $33.0 million in 2025.
• The ZW171 clinical development program was discontinued in September 2025 due to an unfavorable benefit-risk profile.
• Development of ZW220 was paused to facilitate accelerated development of ZW251, making its future clinical development contingent on external funding.
• The company did not fully achieve its 2025 corporate goals with respect to Finance and Partnerships, and Talent (corporate culture).
• The royalty-driven asset aggregation strategy is unproven and may not be successful.
• The company anticipates continued operating losses in the near to medium term.

Risks

• The adoption of a royalty-driven asset aggregation strategy is unproven and may not be successful.
• Strategic transactions could disrupt business, cause dilution to stockholders, and otherwise harm the business.
• Long-term prospects depend upon successfully discovering or acquiring favorable assets and progressing them through preclinical and clinical development.
• The company may not be successful in its efforts to use its therapeutic platforms to build a pipeline of product candidates.
• Partnered product candidates may not meet regulatory and commercial milestones, or experience significant delays.
• Dependence on collaborative relationships with Jazz, BeOne, and J&J for development and commercialization of product candidates.
• The outcome of clinical trials is inherently uncertain, and current and planned trials may not satisfy regulatory requirements.
• Prolonged, delayed, or stopped clinical trials could prevent timely regulatory approval and commercialization, increasing costs and delaying revenue.
• Undesirable side effects from product candidates may delay or prevent marketing approval, or require withdrawal from the market or safety warnings.
• Significant competition from other pharmaceutical and biotechnology companies, including biosimilar products.
• If approved products do not achieve broad market acceptance, revenue will be materially and adversely impacted.
• Current and future healthcare regulations and reimbursement decisions by third-party payors may adversely affect pricing and market acceptance.
• Product liability lawsuits could result in substantial liabilities and limit commercialization efforts.
• Manufacturing difficulties or supply chain disruptions could delay or prevent the availability of product candidates or approved products.
• The company has incurred significant losses since inception and anticipates continued losses, and may never achieve or sustain profitability.
• Additional funding may be required, which may not be available on acceptable terms, or at all, potentially leading to delays or cessation of development programs.
• The terms of the Royalty Pharma loan agreement impose certain restrictions on activities, and failure to comply could accelerate repayment obligations.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing substantial rights.
• Reliance on third-party manufacturers, CROs, and other third parties for operational and administrative aspects of the business.
• Inability to obtain, maintain, and enforce patent and trade secret protection for product candidates and related technology.
• Inability to protect the confidentiality of proprietary information could adversely affect technology and product value.
• Tax law changes could adversely affect business and financial condition.
• Security breaches, data loss, and other disruptions could compromise sensitive information and expose the company to liability.
• Stock price is likely to be volatile and may drop below the price paid by stockholders.
• Delaware law and provisions in the certificate of incorporation and bylaws might delay, discourage, or prevent a change in control.
• Holders of Exchangeable Shares are subject to additional risks.
• Qualifying as a smaller reporting company may make common stock less attractive to investors.
• Failure to maintain an effective system of internal control over financial reporting could harm business and stock price.
• Costs and inefficiencies may result from the 2022 Redomicile Transactions.
• Inability to retain key executives and attract, retain, and motivate qualified personnel.
• Difficulty in managing organizational changes as development and partnering plans advance.
• Failure to meet Nasdaq continued listing requirements.
• Management's broad discretion to use financing proceeds may not yield a favorable return.
• No cash dividends are anticipated for the foreseeable future, requiring stockholders to rely on stock appreciation.
• Principal stockholders could exert substantial influence over the company.
• No assurance that additional shares will be repurchased or at favorable prices under the stock repurchase program.

Future Outlook

The company expects to incur operating losses in the near to medium term as it executes its strategic plan, which emphasizes disciplined capital allocation, focused R&D investment, advancement of partnered programs, and active management of its royalty and asset portfolio. Annual R&D expenses (excluding stock-based compensation) are anticipated to trend lower over the next several years. The ADVANCE research efforts will primarily focus on multispecific antibody and engineered-cytokine platforms, partially supported by early-stage partnerships. ZW1528 is expected to be the first ADVANCE program to enter clinical studies in 2026, with one planned IND filing per annum commencing in 2028 from wholly-owned preclinical candidates. Phase 1 clinical studies for ZW191 and ZW251 will continue in 2026, while advancement of other ADC programs (ZW220, ZW327, ZW418) is contingent on external funding. Jazz Pharmaceuticals expects to complete the sBLA submission for zanidatamab in 1L HER2+ GEA in Q1 2026, with a potential commercial launch in H2 2026. An additional OS interim analysis for Ziihera plus chemotherapy is expected in mid-2026, and EmpowHER-303 trial enrollment is expected to complete in H1 2027, with top-line data in late 2027 or early 2028.

Management Comments

• "Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners."
• "We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders."
• "We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements."

Industry Context

StockSavvy.ai notes the company's strategic shift towards a royalty-driven asset aggregation model is a notable trend in the biotechnology sector, aiming to de-risk development and optimize cash flows, contrasting with traditional R&D-heavy models. The focus on bispecific antibodies and ADCs aligns with high-growth areas in oncology and autoimmune diseases, where competition is intense from major pharmaceutical players. The recent regulatory approvals for zanidatamab position it against established HER2-targeted therapies, highlighting the need for strong clinical differentiation. The increasing scrutiny on drug pricing and the potential impact of legislation like the Inflation Reduction Act of 2022 are significant industry-wide challenges that could affect future revenue streams.

Comparison to Industry Standards

• Ziihera (zanidatamab-hrii) demonstrated a clinically meaningful and statistically significant prolongation of progression-free survival (PFS) with approximately 35% reduction in the risk of disease progression or death versus trastuzumab and chemotherapy in HER2+ GEA, positioning it favorably against a standard HER2-targeted therapy.
• Ziihera plus tislelizumab and chemotherapy showed a median overall survival (OS) of 26.4 months, which is a strong outcome in the context of HER2+ GEA, indicating potential superiority over existing treatments.
• ZW220's design, utilizing a DAR-four format and Fc region mutations, aims to overcome challenges encountered with other NaPi2b-targeted ADCs, including Lifa-V, UpRi, and XMT-1592, suggesting a differentiated approach to minimize toxicities.
• ZW1528's bispecific design for dual blockade of IL-4, IL-13, and IL-33 offers a unique approach to respiratory inflammation compared to monospecific anti-IL-4R mAb or anti-IL-33 clinical benchmarks, with preclinical studies showing superior blockade.
• ZW209's innovative TriTCE design, leveraging obligate cis-T cell binding and conditional CD28 engagement, aims for differentiated long-term cytotoxicity and enhanced T cell proliferation/survival, potentially offering advantages over existing DLL3-targeted therapies like Amgen's IMDELLTRA (tarlatamab) and Boehringer Ingelheim's BI 764532.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2025, the company is not a party to any legal proceedings that, in the opinion of management, would reasonably be expected to have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• On December 28, 2023, EcoR1 Capital, LLC (a principal stockholder) purchased 5,086,521 pre-funded warrants for $50.0 million in a private placement. These warrants were fully net exercised on June 26, 2025, to acquire 5,086,521 shares of common stock.
• On August 10, 2025, Gregory A. Ciongoli, a director, purchased 415,000 shares of common stock for $5.0 million in a private placement.
• On November 18, 2025, Scott Platshon, a former director and now Acting Chief Investment Officer, entered into an employment agreement for a part-time role, including an annual base salary of $70,500 and equity awards (167,000 options and 111,111 RSUs).
• Oleg Nodelman, a director, is the manager of EcoR1 Capital LLC, which beneficially owns a significant portion of the company's common stock.

Stakeholder Impact

• **Shareholders**: Potential for long-term value creation through the royalty-driven asset aggregation strategy and share repurchases, but also faces dilution risk from future financings and stock price volatility. Positive clinical data and regulatory approvals for zanidatamab could increase value, while continued losses pose a risk.
• **Employees**: Management changes and organizational modifications may impact employee morale and retention. The company emphasizes attracting and retaining talent through competitive compensation and benefits.
• **Customers/Patients**: Development of novel biotherapeutics aims to improve standard of care for difficult-to-treat conditions like cancer, inflammation, and autoimmune diseases, offering new treatment options.
• **Strategic Partners**: Continued collaboration with partners like Jazz, BeOne, and J&J is crucial for funding and commercialization, with milestone and royalty payments being a significant revenue source for the company.
• **Creditors**: The $250.0 million non-recourse loan from Royalty Pharma is secured by future Ziihera royalties, providing a clear repayment structure but also imposing covenants and restrictions.

Next Steps

• Jazz expects to complete the supplementary biologic license application (sBLA) submission for zanidatamab in first-line HER2+ locally advanced or metastatic GEA in Q1 2026.
• Jazz expects a potential commercial launch for zanidatamab in 1L HER2+ GEA to take place in the second half of 2026.
• An additional planned overall survival (OS) interim analysis for Ziihera plus chemotherapy is expected in mid-2026.
• Jazz expects to complete enrollment in the EmpowHER-303 trial in the first half of 2027, with a top-line data readout later in 2027 or in early 2028.
• The company expects to submit an IND to commence Phase 1 clinical studies for ZW209 in 2026, with equivalent non-U.S. applications thereafter.
• The company expects to submit a non-U.S. regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2026.
• ZW1528 is currently expected to be the first ADVANCE program to enter clinical studies in 2026.
• The company expects to continue conducting Phase 1 clinical studies for ZW191 and ZW251 during 2026.
• The company intends to advance other ongoing ADC research programs, including potential clinical development of ZW220, ZW327, and ZW418, contingent on partnerships, collaborations, and/or other sources of external funding.
• The company anticipates that development of wholly-owned preclinical candidates from its multispecific antibody portfolio should provide for one planned IND filing per annum commencing in 2028.
• The company intends to continue disseminating scientific findings through peer-reviewed publications and data presentations across its preclinical and clinical programs.

Key Dates

Recommendation

The company has demonstrated strong progress with regulatory approvals for zanidatamab in multiple jurisdictions and positive Phase 3 data for GEA, which are significant value drivers. The $250 million non-recourse loan from Royalty Pharma provides substantial liquidity and validates the value of its royalty streams. However, the company continues to incur significant net losses and has a substantial accumulated deficit, indicating that profitability is still a distant prospect. The new royalty-driven asset aggregation strategy is unproven, and the success of its wholly-owned pipeline candidates is uncertain and contingent on future partnerships and funding. While there are clear positive catalysts, the inherent risks of drug development and the company's financial position suggest a "hold" is appropriate for investors to monitor the execution of its strategy and path to sustainable profitability.

Keywords

Biotechnology, Oncology, Antibody-Drug Conjugates, Bispecific Antibodies, HER2, Zanidatamab, Ziihera, Pasritamig, Clinical Trials, Regulatory Approval, Royalty Aggregation, Pharmaceutical Partnerships, Drug Development, SEC Filing, Financial Results, Biotherapeutics, Autoimmune Disease, Inflammation, Capital Allocation, Stock Repurchase, Royalty Pharma